PUFA ω-3 and ω-6 biomarkers and sleep: a pooled analysis of cohort studies on behalf of the Fatty Acids and Outcomes Research Consortium (FORCE).
biomarkers
diet
fatty acids
omega-3
public health
sleep quality
Journal
The American journal of clinical nutrition
ISSN: 1938-3207
Titre abrégé: Am J Clin Nutr
Pays: United States
ID NLM: 0376027
Informations de publication
Date de publication:
04 03 2022
04 03 2022
Historique:
received:
17
09
2021
accepted:
07
12
2021
pubmed:
18
12
2021
medline:
28
4
2022
entrez:
17
12
2021
Statut:
ppublish
Résumé
n-3 and n-6 PUFAs have physiologic roles in sleep processes, but little is known regarding circulating n-3 and n-6 PUFA and sleep parameters. We sought to assess associations between biomarkers of n-3 and n-6 PUFA intake with self-reported sleep duration and difficulty falling sleeping in the Fatty Acids and Outcome Research Consortium. Harmonized, de novo, individual-level analyses were performed and pooled across 12 cohorts. Participants were 35-96 y old and from 5 nations. Circulating measures included α-linolenic acid (ALA), EPA, docosapentaenoic acid (DPA), DHA, EPA + DPA + DHA, linoleic acid, and arachidonic acid. Sleep duration (10 cohorts, n = 18,791) was categorized as short (≤6 h), 7-8 h (reference), or long (≥9 h). Difficulty falling asleep (8 cohorts, n = 12,500) was categorized as yes or no. Associations between PUFAs, sleep duration, and difficulty falling sleeping were assessed by cross-sectional multinomial logistic regression using standardized protocols and covariates. Cohort-specific multivariable-adjusted ORs per quintile of PUFAs were pooled with inverse-variance weighted meta-analysis. In pooled analysis adjusted for sociodemographic characteristics and health status, participants with higher very long-chain n-3 PUFAs were less likely to have long sleep duration. In the top compared with the bottom quintiles, the multivariable-adjusted ORs (95% CIs) for long sleep were 0.78 (95% CI: 0.65, 0.95) for DHA and 0.76 (95% CI: 0.63, 0.93) for EPA + DPA + DHA. Significant associations for ALA and n-6 PUFA with short sleep duration or difficulty falling sleeping were not identified. Participants with higher concentrations of very long-chain n-3 PUFAs were less likely to have long sleep duration. While objective biomarkers reduce recall bias and misclassification, the cross-sectional design limits assessment of the temporal nature of this relation. These novel findings across 12 cohorts highlight the need for experimental and biological assessments of very long-chain n-3 PUFAs and sleep duration.
Sections du résumé
BACKGROUND
n-3 and n-6 PUFAs have physiologic roles in sleep processes, but little is known regarding circulating n-3 and n-6 PUFA and sleep parameters.
OBJECTIVES
We sought to assess associations between biomarkers of n-3 and n-6 PUFA intake with self-reported sleep duration and difficulty falling sleeping in the Fatty Acids and Outcome Research Consortium.
METHODS
Harmonized, de novo, individual-level analyses were performed and pooled across 12 cohorts. Participants were 35-96 y old and from 5 nations. Circulating measures included α-linolenic acid (ALA), EPA, docosapentaenoic acid (DPA), DHA, EPA + DPA + DHA, linoleic acid, and arachidonic acid. Sleep duration (10 cohorts, n = 18,791) was categorized as short (≤6 h), 7-8 h (reference), or long (≥9 h). Difficulty falling asleep (8 cohorts, n = 12,500) was categorized as yes or no. Associations between PUFAs, sleep duration, and difficulty falling sleeping were assessed by cross-sectional multinomial logistic regression using standardized protocols and covariates. Cohort-specific multivariable-adjusted ORs per quintile of PUFAs were pooled with inverse-variance weighted meta-analysis.
RESULTS
In pooled analysis adjusted for sociodemographic characteristics and health status, participants with higher very long-chain n-3 PUFAs were less likely to have long sleep duration. In the top compared with the bottom quintiles, the multivariable-adjusted ORs (95% CIs) for long sleep were 0.78 (95% CI: 0.65, 0.95) for DHA and 0.76 (95% CI: 0.63, 0.93) for EPA + DPA + DHA. Significant associations for ALA and n-6 PUFA with short sleep duration or difficulty falling sleeping were not identified.
CONCLUSIONS
Participants with higher concentrations of very long-chain n-3 PUFAs were less likely to have long sleep duration. While objective biomarkers reduce recall bias and misclassification, the cross-sectional design limits assessment of the temporal nature of this relation. These novel findings across 12 cohorts highlight the need for experimental and biological assessments of very long-chain n-3 PUFAs and sleep duration.
Identifiants
pubmed: 34918026
pii: S0002-9165(22)10561-7
doi: 10.1093/ajcn/nqab408
pmc: PMC8895226
doi:
Substances chimiques
Biomarkers
0
Fatty Acids
0
Fatty Acids, Omega-3
0
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
864-876Subventions
Organisme : NHLBI NIH HHS
ID : R35 HL135818
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the American Society for Nutrition.
Références
Am J Med. 2015 Mar;128(3):268-75.e2
pubmed: 25447616
Neurology. 1997 Apr;48(4):904-11
pubmed: 9109875
J Acad Nutr Diet. 2018 Sep;118(9):1591-1602
pubmed: 30146071
J Nutr. 1999 Nov;129(11):2074-80
pubmed: 10539787
Sleep Med Rev. 2011 Dec;15(6):411-8
pubmed: 22024172
Sleep Med. 2016 Jan;17:126-8
pubmed: 26847986
Nutrients. 2021 Jan 16;13(1):
pubmed: 33467135
Arch Gen Psychiatry. 2002 Feb;59(2):131-6
pubmed: 11825133
J Am Heart Assoc. 2018 Aug 7;7(15):e008552
pubmed: 30371228
Circulation. 2019 May 21;139(21):2422-2436
pubmed: 30971107
J Nutr. 2008 Sep;138(9):1719-24
pubmed: 18716175
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Sleep. 2004 May 1;27(3):440-4
pubmed: 15164896
Eur J Prev Cardiol. 2014 Jan;21(1):57-64
pubmed: 22942213
J Lipid Res. 1998 Jul;39(7):1397-403
pubmed: 9684742
Am J Epidemiol. 2005 Aug 15;162(4):373-81
pubmed: 16014782
Med Hypotheses. 1998 Feb;50(2):139-45
pubmed: 9572569
Prostaglandins Leukot Essent Fatty Acids. 2009 Feb-Mar;80(2-3):85-91
pubmed: 19269799
J Am Geriatr Soc. 2000 Feb;48(2):115-23
pubmed: 10682939
J Sleep Res. 2013 Oct;22(5):569-72
pubmed: 23432533
J Epidemiol. 2000 Mar;10(2):87-93
pubmed: 10778032
Sleep Med. 2010 Feb;11(2):180-4
pubmed: 20005774
Lancet Diabetes Endocrinol. 2017 Dec;5(12):965-974
pubmed: 29032079
Sleep. 2004 Feb 1;27(1):51-4
pubmed: 14998237
J Sleep Res. 2014 Aug;23(4):364-88
pubmed: 24605819
JAMA Intern Med. 2016 Aug 1;176(8):1155-66
pubmed: 27357102
Diabetes Care. 2003 Feb;26(2):380-4
pubmed: 12547866
Am J Pathol. 2010 Oct;177(4):1576-91
pubmed: 20813960
Biochim Biophys Acta. 2010 Feb;1801(2):95-9
pubmed: 19879958
Arch Intern Med. 2003 Jan 27;163(2):205-9
pubmed: 12546611
Arch Intern Med. 2005 Apr 25;165(8):863-7
pubmed: 15851636
J Nutr. 2020 Mar 1;150(3):592-598
pubmed: 31758194
Proc Natl Acad Sci U S A. 2001 May 22;98(11):6402-6
pubmed: 11353819
Neuron. 2019 Aug 21;103(4):686-701.e8
pubmed: 31248729
Sleep. 2015 Jun 01;38(6):843-4
pubmed: 26039963
Sleep Med. 2005 Jan;6(1):23-7
pubmed: 15680291
Cent Nerv Syst Agents Med Chem. 2011 Sep 1;11(3):189-96
pubmed: 21919868
J Clin Sleep Med. 2011 Aug 15;7(4):391-6
pubmed: 21897776
Sleep Med Rev. 2007 Oct;11(5):341-60
pubmed: 17625932
Sleep. 2020 Mar 12;43(3):
pubmed: 31616945
Int Rev Psychiatry. 2006 Apr;18(2):107-18
pubmed: 16777665